ML 786 dihydrochloride

Name: ML 786 dihydrochloride
Brand: Tocris Bioscience
SKU: 5036

Cat. No. 5036 1 次引用提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Discontinued Product

5036 has been discontinued.

View all Raf Kinases products.

说明： Potent Raf kinase inhibitor; orally bioavailable

别名： BGB659

化学名： 3-(1-Amino-1-methylethyl)-N-[(2R)-1,2,3,4-tetrahydro-7-oxo-1,8-naphthryridin-4-yl)oxy]-2-naphthalenyl]-5-benzamide dihydrochloride

纯度： ≥98% (HPLC)

说明书

引用文献 (1)

生物活性技术数据说明书参考文献

生物活性 for ML 786 dihydrochloride

Potent Raf kinase inhibitor (IC₅₀ values are 2.1, 2.5 and 4.2 nM for B-Raf^V600E, C-Raf and wild-type B-Raf respectively). Also inhibits Abl-1, DDR2, EPHA2 and RET tyrosine kinase activity. Inhibits pERK formation and attenuates tumor growth in melanoma cell xenografts expressing the B-Raf^V600E mutation in vivo. Orally bioavailable.

技术数据 for ML 786 dihydrochloride

分子量	611.48
公式	C₂₉H₂₉F₃N₄O₃.2HCl
储存	Store at +4°C
纯度	≥98% (HPLC)
CAS Number	1237536-18-3
PubChem ID	90488999
InChI Key	DNMWHXHMDZCGEX-GHVWMZMZSA-N
Smiles	O=C(N[C@@H]2CCC(C=CC(OC4=C(CC5)C(NC=C4)=NC5=O)=C3)=C3C2)C1=CC(C(F)(F)F)=CC(C(N)(C)C)=C1.Cl.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for ML 786 dihydrochloride

分析证书/产品说明书

化学品安全技术说明书

参考文献 for ML 786 dihydrochloride

参考文献是支持产品生物活性的出版物。

Gould et al (2011) Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. J.Med.Chem. 54 1836 PMID: 21341678

Sase et al (2018) Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2-amplified gastric cancer. Mol.Cancer Ther. 17 2217 PMID: 30045926

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Raf Kinase Inhibitors

关键词: ML 786 dihydrochloride, ML 786 dihydrochloride supplier, ML786, dihydrochloride, potent, raf, kinase, inhibitors, inhibits, b-raf, c-raf, V600E, mutation, tyrosine, kinases, BGB659, Raf, Kinase, 5036, Tocris Bioscience

1 篇 ML 786 dihydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 ML 786 dihydrochloride 的部分引用包括：

Sase et al (2018) Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2- amplified gastric cancer. Mol.Cancer Ther. PMID: 30045926